Header Logo

JENNIFER WARGO

TitleAssociate Professor
InstitutionMD Anderson
DepartmentSurgical Oncology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, Yates MS, Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, Yates MS. Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion. Clin Cancer Res. 2024 Nov 15; 30(22):5073-5082. PMID: 38922360; PMCID: PMC11567806.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    2. Angelidakis G, Chemaly RF, Sahasrabhojane PV, Morado-Aramburo O, Jiang Y, Bhatti MM, Shpall E, Hosing C, Jain P, Mahadeo KM, Khawaja F, Elhajj P, Wargo JA, Jenq RR, Ajami NJ, Kebriaei P, Ariza-Heredia EJ. Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study. Vaccines (Basel). 2024 Sep 19; 12(9). PMID: 39340100; PMCID: PMC11436035.
      Citations:    
    3. Rahal Z, Liu Y, Peng F, Yang S, Jamal MA, Sharma M, Moreno H, Damania AV, Wong MC, Ross MC, Sinjab A, Zhou T, Chen M, Tarifa Reischle I, Feng J, Chukwuocha C, Tang E, Abaya C, Lim JK, Leung CH, Lin HY, Deboever N, Lee JJ, Sepesi B, Gibbons DL, Wargo JA, Fujimoto J, Wang L, Petrosino JF, Ajami NJ, Jenq RR, Moghaddam SJ, Cascone T, Hoffman K, Kadara H. Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment. Cancer Immunol Res. 2024 Sep 13. PMID: 39269772.
      Citations: 1     Fields:    
    4. Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Xiao Y, Fan C, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Enkhbayar A, Mohammed A, Schmiester M, King KY, Britton RA, Reddy P, Wong MC, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Katsamakis Z, Smith N, Burgos da Silva M, Ponce DM, Peled JU, van den Brink MRM, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe. 2024 Sep 11; 32(9):1621-1636.e6. PMID: 39214085; PMCID: PMC11441101.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    5. Boe RH, Triandafillou CG, Lazcano R, Wargo JA, Raj A. Spatial transcriptomics reveals influence of microenvironment on intrinsic fates in melanoma therapy resistance. bioRxiv. 2024 Jul 02. PMID: 39005406; PMCID: PMC11244927.
      Citations:    
    6. Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE. Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2024; 19(7):e0306658. PMID: 38950005; PMCID: PMC11216593.
      Citations:    Fields:    
    7. Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautam S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Aunin? JG, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA, Aunins J. Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov. 2024 Jul 01; 14(7):1161-1175. PMID: 38588588; PMCID: PMC11215408.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    8. Emens LA, Romero PJ, Anderson AC, Bruno TC, Capitini CM, Collyar D, Gulley JL, Hwu P, Posey AD, Silk AW, Wargo JA. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J Immunother Cancer. 2024 Jun 19; 12(6). PMID: 38901879; PMCID: PMC11191773.
      Citations: 8     Fields:    Translation:Humans
    9. Mishra AK, Mahmud I, Lorenzi PL, Jenq RR, Wargo JA, Ajami NJ, Peterson CB. TARO: tree-aggregated factor regression for microbiome data integration. Bioinformatics. 2024 06 03; 40(6). PMID: 38788190; PMCID: PMC11193058.
      Citations:    Fields:    Translation:Humans
    10. Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT, Burton EM, Tawbi HA, Davies MA. Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2024 Jun; 30(6):1787. PMID: 38649781; PMCID: PMC11186776.
      Citations:    Fields:    
    11. Wargo JA, Ajami NJ, Daniel-MacDougall CR. Jennifer A. Wargo, Nadim J. Ajami, and Carrie R. Daniel-MacDougall. Cell Rep Med. 2024 Apr 16; 5(4):101509. PMID: 38631287; PMCID: PMC11143382.
      Citations:    Fields:    
    12. Swanton C, Bernard E, Abbosh C, Andr? F, Auwerx J, Balmain A, Bar-Sagi D, Bernards R, Bullman S, DeGregori J, Elliott C, Erez A, Evan G, Febbraio MA, Hidalgo A, Jamal-Hanjani M, Joyce JA, Kaiser M, Lamia K, Locasale JW, Loi S, Malanchi I, Merad M, Musgrave K, Patel KJ, Quezada S, Wargo JA, Weeraratna A, White E, Winkler F, Wood JN, Vousden KH, Hanahan D. Embracing cancer complexity: Hallmarks of systemic disease. Cell. 2024 Mar 28; 187(7):1589-1616. PMID: 38552609.
      Citations: 40     Fields:    Translation:Humans
    13. Belotserkovsky I, Stabryla LM, Hunter M, Allegretti J, Callahan BJ, Carlson PE, Daschner PJ, Goudarzi M, Guyard C, Jackson SA, Rao K, Servetas SL, Sokol H, Wargo JA, Novick S. Standards for fecal microbiota transplant: Tools and therapeutic advances. Biologicals. 2024 May; 86:101758. PMID: 38518435.
      Citations: 2     Fields:    Translation:HumansCells
    14. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641. PMID: 38351182.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    15. Liu Q, Adhikari E, Lester DK, Fang B, Johnson JO, Tian Y, Mockabee-Macias AT, Izumi V, Guzman KM, White MG, Koomen JM, Wargo JA, Messina JL, Qi J, Lau EK. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation. Nat Commun. 2024 Feb 07; 15(1):1148. PMID: 38326303; PMCID: PMC10850104.
      Citations: 1     Fields:    Translation:HumansCells
    16. Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine. 2023 Dec; 98:104873. PMID: 38040541; PMCID: PMC10755114.
      Citations: 1     Fields:    Translation:Humans
    17. Jain R, Hadjigeorgiou A, Harkos C, Mishra A, Morad G, Johnson S, Ajami N, Wargo J, Munn L, Stylianopoulos T. Dissecting the Impact of the Gut Microbiome on Cancer Immunotherapy. Res Sq. 2023 Nov 30. PMID: 38076985; PMCID: PMC10705708.
      Citations: 2     
    18. Holder AM, Wargo JA, Ross MI. Correction: Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma. Ann Surg Oncol. 2023 Nov; 30(12):7688. PMID: 37661225.
      Citations:    Fields:    
    19. Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Dieli-Conwright CM, Lazar AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, Li Y, Wargo JA, McAllister F, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome. Clin Cancer Res. 2023 11 01; 29(21):4361-4372. PMID: 37724990; PMCID: PMC10618653.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    20. Colbert LE, El Alam MB, Wang R, Karpinets T, Lo D, Lynn EJ, Harris TA, Elnaggar JH, Yoshida-Court K, Tomasic K, Bronk JK, Sammouri J, Yanamandra AV, Olvera AV, Carlin LG, Sims T, Delgado Medrano AY, Napravnik TC, O'Hara M, Lin D, Abana CO, Li HX, Eifel PJ, Jhingran A, Joyner M, Lin L, Ramondetta LM, Futreal AM, Schmeler KM, Mathew G, Dorta-Estremera S, Zhang J, Wu X, Ajami NJ, Wong M, Taniguchi C, Petrosino JF, Sastry KJ, Okhuysen PC, Martinez SA, Tan L, Mahmud I, Lorenzi PL, Wargo JA, Klopp AH. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023 11 13; 41(11):1945-1962.e11. PMID: 37863066; PMCID: PMC10841640.
      Citations: 3     Fields:    Translation:HumansCells
    21. Mishra AK, Mahmud I, Lorenzi PL, Jenq RR, Wargo JA, Ajami NJ, Peterson CB. TARO: tree-aggregated factor regression for microbiome data integration. bioRxiv. 2023 Oct 19. PMID: 37904958; PMCID: PMC10614880.
      Citations: 1     
    22. Witt RG, Cass SH, Tran T, Damania A, Nelson EE, Sirmans E, Burton EM, Chelvanambi M, Johnson S, Tawbi HA, Gershenwald JE, Davies MA, Spencer C, Mishra A, Wong MC, Ajami NJ, Peterson CB, Daniel CR, Wargo JA, McQuade JL, Nelson KC. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol. 2023 10 01; 159(10):1076-1084. PMID: 37647056; PMCID: PMC10469295.
      Citations: 1     Fields:    Translation:Humans
    23. Borthwick Bowen M, Helmink BA, Wargo JA, Yates MS. TIME for Bugs: The Immune Microenvironment and Microbes in Precancer. Cancer Prev Res (Phila). 2023 09 01; 16(9):497-505. PMID: 37428011; PMCID: PMC10542944.
      Citations:    Fields:    Translation:Humans
    24. Holder AM, Wargo JA, Ross MI. Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma. Ann Surg Oncol. 2023 Nov; 30(12):6953-6957. PMID: 37597079.
      Citations:    Fields:    
    25. Seo YD, Ajami N, Wargo JA. Using gut microorganisms to treat cancer. Nat Med. 2023 08; 29(8):1910-1911. PMID: 37420098.
      Citations:    Fields:    Translation:Humans
    26. Goyal Y, Busch GT, Pillai M, Li J, Boe RH, Grody EI, Chelvanambi M, Dardani IP, Emert B, Bodkin N, Braun J, Fingerman D, Kaur A, Jain N, Ravindran PT, Mellis IA, Kiani K, Alicea GM, Fane ME, Ahmed SS, Li H, Chen Y, Chai C, Kaster J, Witt RG, Lazcano R, Ingram DR, Johnson SB, Wani K, Dunagin MC, Lazar AJ, Weeraratna AT, Wargo JA, Herlyn M, Raj A. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature. 2023 Aug; 620(7974):651-659. PMID: 37468627; PMCID: PMC10628994.
      Citations: 16     Fields:    Translation:HumansCells
    27. White MG, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Lutter-Berkova Z, Chang GJ, Futreal A, Wargo JA, Ajami NJ, Kopetz S, You YN. Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation With Response to Neoadjuvant Therapy. Ann Surg. 2023 10 01; 278(4):538-548. PMID: 37465976; PMCID: PMC10528779.
      Citations:    Fields:    Translation:Humans
    28. Baruch EN, Nagarajan P, Gleber-Netto FO, Rao X, Xie T, Akhter S, Adewale A, Shajedul I, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunaratne P, Goepfert RP, Khushalani N, Wang J, Watowich S, Calin GA, Migden MR, Vermeer P, D'Silva N, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo J, Myers JN, Gross ND, Amit M. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Res Sq. 2023 Jul 18. PMID: 37503252; PMCID: PMC10371163.
      Citations:    
    29. Lucci A, Addanki S, Chiang YJ, Meas S, Sarli VN, Upshaw JR, Manchem M, Patel SP, Wargo JA, Gershenwald JE, Ross MI. Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma. Cancers (Basel). 2023 Jul 15; 15(14). PMID: 37509290; PMCID: PMC10377914.
      Citations:    
    30. Chelvanambi M, Wargo JA. MAdCAM-1: a newly identified microbial 'gut check' for T cells. Trends Immunol. 2023 08; 44(8):568-570. PMID: 37451906.
      Citations: 1     Fields:    Translation:HumansCells
    31. Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino MS, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol. 2023 09; 34(9):796-805. PMID: 37414216; PMCID: PMC11289780.
      Citations:    Fields:    Translation:Humans
    32. Thomas AM, Fidelle M, Routy B, Kroemer G, Wargo JA, Segata N, Zitvogel L. Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat Rev Clin Oncol. 2023 09; 20(9):583-603. PMID: 37365438; PMCID: PMC11258874.
      Citations: 11     Fields:    Translation:Humans
    33. Park JS, Gazzaniga FS, Wu M, Luthens AK, Gillis J, Zheng W, LaFleur MW, Johnson SB, Morad G, Park EM, Zhou Y, Watowich SS, Wargo JA, Freeman GJ, Kasper DL, Sharpe AH. Publisher Correction: Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 Jun; 618(7966):E27. PMID: 37264079.
      Citations:    Fields:    
    34. Seo YD, Wargo JA. From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer. Cell Rep Med. 2023 05 16; 4(5):101039. PMID: 37196631; PMCID: PMC10213830.
      Citations: 1     Fields:    Translation:AnimalsCells
    35. Park JS, Gazzaniga FS, Wu M, Luthens AK, Gillis J, Zheng W, LaFleur MW, Johnson SB, Morad G, Park EM, Zhou Y, Watowich SS, Wargo JA, Freeman GJ, Kasper DL, Sharpe AH. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 05; 617(7960):377-385. PMID: 37138075; PMCID: PMC10219577.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    36. Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JC, Kwong LN. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569. PMID: 36820825; PMCID: PMC10159986.
      Citations:    Fields:    Translation:AnimalsCells
    37. Asare EA, Fisher SB, Chiang YJ, Haydu LE, Patel SH, Keung EZ, Lucci A, Wargo J, Gershenwald JE, Ross MI, Lee JE. Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. J Surg Oncol. 2023 Aug; 128(2):313-321. PMID: 37010038.
      Citations:    Fields:    Translation:Humans
    38. Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905. PMID: 36997799; PMCID: PMC10115650.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    39. Elnaggar JH, Huynh VO, Lin D, Hillman RT, Abana CO, El Alam MB, Tomasic KC, Karpinets TV, Kouzy R, Phan JL, Wargo J, Holliday EB, Das P, Mezzari MP, Ajami NJ, Lynn EJ, Minsky BD, Morris VK, Milbourne A, Messick CA, Klopp AH, Futreal PA, Taniguchi CM, Schmeler KM, Colbert LE. HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development. Front Immunol. 2023; 14:1051431. PMID: 37063829; PMCID: PMC10090447.
      Citations: 2     Fields:    Translation:Humans
    40. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604. PMID: 36928818; PMCID: PMC10033402.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    41. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23. PMID: 36894629; PMCID: PMC10033416.
      Citations: 1     Fields:    
    42. Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq. 2023 Jan 31. PMID: 36778495; PMCID: PMC9915792.
      Citations:    
    43. Knisely A, Seo YD, Wargo JA, Chelvanambi M. Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. Cancers (Basel). 2023 Jan 27; 15(3). PMID: 36765735; PMCID: PMC9913233.
      Citations: 2     
    44. Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer. 2023 02; 4(2):222-239. PMID: 36690875; PMCID: PMC9970875.
      Citations: 2     Fields:    Translation:HumansCells
    45. Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of checkpoint blockade-associated toxicity. J Exp Med. 2023 03 06; 220(3). PMID: 36622383; PMCID: PMC9836236.
      Citations: 4     Fields:    Translation:Humans
    46. Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164. PMID: 36166093; PMCID: PMC10311539.
      Citations: 4     Fields:    Translation:Humans
    47. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3. PMID: 36627494.
      Citations:    Fields:    
    48. Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, Lu J, Nunez Cortes AK, Uprety N, Ensley E, Muniz-Feliciano L, Laskowski TJ, Moyes JS, Daher M, Mendt M, Kerbauy LN, Shanley M, Li L, Lim FLWI, Shaim H, Li Y, Konopleva M, Green M, Wargo J, Shpall EJ, Chen K, Rezvani K. Activated B cells suppress T-cell function through metabolic competition. J Immunother Cancer. 2022 12; 10(12). PMID: 36543374; PMCID: PMC9772692.
      Citations: 1     Fields:    
    49. Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445. PMID: 36383683; PMCID: PMC10028729.
      Citations: 6     Fields:    Translation:AnimalsCells
    50. Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med. 2023 02 06; 220(2). PMID: 36367776; PMCID: PMC9664499.
      Citations: 8     Fields:    Translation:Animals
    51. Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov. 2022 11 02; 12(11):2626-2645. PMID: 36098652; PMCID: PMC9633381.
      Citations:    
    52. Amaria RN, Postow M, Burton EM, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA, Tetzlaff MT. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160. PMID: 36289334; PMCID: PMC9607737.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    53. Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484. PMID: 36313661; PMCID: PMC9597628.
      Citations: 2     
    54. Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Pe?a J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022 09 29; 185(20):3705-3719.e14. PMID: 36179667; PMCID: PMC9542352.
      Citations: 20     Fields:    Translation:AnimalsCells
    55. Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribeiro R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med. 2022 11; 28(11):2344-2352. PMID: 36138151.
      Citations:    
    56. White MG, Wargo JA. The Microbiome in Gastrointestinal Cancers. Gastroenterol Clin North Am. 2022 09; 51(3):667-680. PMID: 36153116.
      Citations: 1     Fields:    Translation:Humans
    57. Bhutiani N, Wargo JA. Gut microbes as biomarkers of ICI response - sharpening the focus. Nat Rev Clin Oncol. 2022 08; 19(8):495-496. PMID: 35449306.
      Citations:    Fields:    Translation:Humans
    58. van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI, International Neoadjuvant Melanoma Consortium (INMC), Duprat Neto JP. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Aug; 29(8):5241-5242. PMID: 35426590.
      Citations:    Fields:    
    59. Michikawa C, Gopalakrishnan V, Harrandah AM, Karpinets TV, Garg RR, Chu RA, Park YP, Chukkapallia SS, Yadlapalli N, Erikson-Carter KC, Gleber-Netto FO, Sayour E, Progulske-Fox A, Chan EKL, Wu X, Zhang J, Jobin C, Wargo JA, Pickering CR, Myers JN, Silver N. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia. 2022 09; 31:100813. PMID: 35834946; PMCID: PMC9287628.
      Citations:    Fields:    Translation:HumansCells
    60. Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Yu X, Song X, Mao X, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SE, Forget MA. Multi-modal molecular programs regulate melanoma cell state. Nat Commun. 2022 07 09; 13(1):4000. PMID: 35810190; PMCID: PMC9271073.
      Citations:    Fields:    Translation:HumansCells
    61. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA, Conforti F, Pala L. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803. PMID: 35705814; PMCID: PMC10071594.
      Citations: 1     Fields:    Translation:HumansAnimals
    62. Chelvanambi M, Wargo JA. Trust your gut when it comes to driving CARs. Med. 2022 05 13; 3(5):281-283. PMID: 35584646.
      Citations:    Translation:HumansCells
    63. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6. PMID: 35537412; PMCID: PMC9221568.
      Citations:    Fields:    Translation:HumansAnimalsCells
    64. Park EM, Chelvanambi M, Bhutiani N, Wargo JA, Kroemer G, Zitvogel L. Targeting the gut and tumor microbiota in cancer. Nat Med. 2022 04; 28(4):690-703. PMID: 35440726.
      Citations: 2     Fields:    Translation:Humans
    65. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735. PMID: 35419587.
      Citations:    Fields:    
    66. Dono A, Nickles J, Rodriguez-Armendariz AG, McFarland BC, Ajami NJ, Ballester LY, Wargo JA, Esquenazi Y. Glioma and the gut-brain axis: opportunities and future perspectives. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac054. PMID: 35591978; PMCID: PMC9113089.
      Citations:    
    67. Cascone T, Chelvanambi M, Wargo JA. Immunotherapy response-associated Akkermansia: canary in a coal mine? Trends Immunol. 2022 05; 43(5):337-339. PMID: 35397955.
      Citations:    Fields:    Translation:HumansAnimalsCells
    68. Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BA. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):437-445. PMID: 35278716.
      Citations:    Fields:    
    69. Witt RG, Erstad DJ, Wargo JA. Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Ther Adv Med Oncol. 2022; 14:17588359221083052. PMID: 35251322; PMCID: PMC8894940.
      Citations: 1     
    70. Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweek R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ, Nandakumar S. Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunol Res. 2022 03 01; 10(3):303-313. PMID: 35013003; PMCID: PMC8898286.
      Citations:    Fields:    Translation:Humans
    71. Freeman SS, Sade-Feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, LaSalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Carrot-Zhang J, Ha G, Lin Z, Chen JH, Barzily-Rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-Rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N, Aguet F. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep Med. 2022 02 15; 3(2):100500. PMID: 35243413; PMCID: PMC8861826.
      Citations: 1     Fields:    Translation:HumansCells
    72. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2022 Feb 03; 185(3):576. PMID: 35120665.
      Citations: 1     Fields:    
    73. Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022 04; 22(4):195-207. PMID: 35105962.
      Citations: 5     Fields:    Translation:Humans
    74. van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI, International Neoadjuvant Melanoma Consortium (INMC), Duprat Neto JP. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Jun; 29(6):3694-3708. PMID: 35089452.
      Citations: 1     Fields:    Translation:Humans
    75. Servetas SL, Daschner PJ, Guyard C, Thomas V, Affagard H, Sergaki C, Wargo JA, Wu GD, Sabot P, Sokol H. Evolution of FMT - From early clinical to standardized treatments. Biologicals. 2022 Apr; 76:31-35. PMID: 35086768.
      Citations:    Fields:    Translation:HumansCells
    76. Colbert LE, El MB, Lynn EJ, Bronk J, Karpinets TV, Wu X, Chapman BV, Sims TT, Lin D, Kouzy R, Sammouri J, Biegert G, Delgado Medrano AY, Olvera A, Sastry KJ, Eifel PJ, Jhingran A, Lin L, Ramondetta LM, Futreal AP, Jazaeri AA, Schmeler KM, Yue J, Mitra A, Yoshida-Court K, Wargo JA, Solley TN, Hegde V, Nookala SS, Yanamandra AV, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday EB, Minsky BD, Koong AC, Koay EJ, Das P, Taniguchi CM, Klopp A. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271. PMID: 35045973.
      Citations:    Fields:    Translation:HumansCells
    77. Erstad DJ, Witt RG, Wargo JA. Neoadjuvant therapy for melanoma: new and evolving concepts. Clin Adv Hematol Oncol. 2022 Jan; 20(1):47-55. PMID: 35060962; PMCID: PMC9103060.
      Citations:    Fields:    Translation:Humans
    78. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640. PMID: 34941392; PMCID: PMC8970537.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    79. Chelvanambi M, Wargo JA. More fuel for the fire: Gut microbes and toxicity to immune agonist antibodies in cancer. Cell Rep Med. 2021 12 21; 2(12):100482. PMID: 35028621; PMCID: PMC8715066.
      Citations:    Fields:    Translation:Humans
    80. Wang Y, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JE. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol. 2022 07; 142(7):2046-2049.e3. PMID: 34952092; PMCID: PMC9209587.
      Citations: 1     Fields:    Translation:Humans
    81. Witt RG, Cope B, Chiang YJ, Newhook T, Lillemoe H, Tzeng CD, Chen IB, Fisher SB, Lucci A, Wargo JA, Lee JE, Ross MI, Gershenwald JE, Robinson J, Keung EZ. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol. 2022 Mar; 125(4):719-729. PMID: 34904258; PMCID: PMC9108995.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    82. St Paul M, Saibil SD, Han S, Israni-Winger K, Lien SC, Laister RC, Sayad A, Penny S, Amaria RN, Haydu LE, Garcia-Batres CR, Kates M, Mulder DT, Gold MJ, Tran CW, Elford AR, Nguyen LT, Pugh TJ, Pinto DM, Wargo JA, Ohashi PS, Robert-Tissot C. Coenzyme A fuels T?cell anti-tumor immunity. Cell Metab. 2021 12 07; 33(12):2415-2427.e6. PMID: 34879240.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    83. White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880. PMID: 34777916; PMCID: PMC8583008.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    84. Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21). PMID: 34771465; PMCID: PMC8582574.
      Citations:    
    85. Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, Johnson SB, Schwarz B, Bohrnsen E, Cogdill AP, Bosio CM, Wargo JA, Lee MP, Goldszmid RS, Lop?s A. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021 10 14; 184(21):5338-5356.e21. PMID: 34624222; PMCID: PMC8650838.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    86. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021 10 14; 184(21):5309-5337. PMID: 34624224; PMCID: PMC8767569.
      Citations: 36     Fields:    Translation:HumansAnimals
    87. Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375. PMID: 34253579; PMCID: PMC8752638.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    88. Baruch EN, Gaglani T, Wargo JA. Fecal microbiota transplantation as a mean of overcoming immunotherapy-resistant cancers - hype or hope? Ther Adv Med Oncol. 2021; 13:17588359211045853. PMID: 34603515; PMCID: PMC8481703.
      Citations: 1     
    89. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606. PMID: 34556668; PMCID: PMC8460828.
      Citations: 13     Fields:    Translation:HumansCells
    90. Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045. PMID: 34413300; PMCID: PMC8376947.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    91. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA, Fluckiger A, Raoult D. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441. PMID: 34239137; PMCID: PMC11107795.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    92. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565. PMID: 34187851; PMCID: PMC8711237.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    93. Lu Y, Ng AHC, Chow FE, Everson RG, Helmink BA, Tetzlaff MT, Thakur R, Wargo JA, Cloughesy TF, Prins RM, Heath JR. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nat Commun. 2021 06 29; 12(1):4031. PMID: 34188042; PMCID: PMC8241935.
      Citations: 6     Fields:    Translation:HumansCells
    94. Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, Saponara M, Orsolini G, Zagami P, De Marinis F, Tortora G, Bria E, Minucci S, Joffe H, Veronesi P, Wargo J, Rosenthal R, Swanton C, Mantovani A, Gelber RD, Viale G, Goldhirsch A, Giaccone G, Nicol? E. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clin Cancer Res. 2021 08 01; 27(15):4311-4324. PMID: 34016641; PMCID: PMC7611463.
      Citations: 7     Fields:    Translation:Humans
    95. Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul; 28(7):3480-3489. PMID: 33856603; PMCID: PMC8636723.
      Citations:    Fields:    Translation:Humans
    96. Baruch EN, Wang J, Wargo JA. Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect. Cancer Immunol Res. 2021 04; 9(4):365-370. PMID: 34003768.
      Citations: 6     Fields:    Translation:HumansCells
    97. Sepich-Poore GD, Straussman R, Hasty J, Wargo JA, Knight R, Zitvogel L. The microbiome and human cancer. Science. 2021 03 26; 371(6536). PMID: 33766858; PMCID: PMC8767999.
      Citations: 68     Fields:    Translation:HumansCells
    98. Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, Ketelaars SLC, Cheng K, Vervier K, Shental N, Bussi Y, Rotkopf R, Levy R, Benedek G, Trabish S, Dadosh T, Levin-Zaidman S, Geller LT, Wang K, Greenberg P, Yagel G, Peri A, Fuks G, Bhardwaj N, Reuben A, Hermida L, Johnson SB, Shropshire WC, Bernatchez C, Haymaker C, Arora R, Roitman L, Eilam R, Weinberger A, Lotan-Pompan M, Lotem M, Admon A, Levin Y, Lawley TD, Adams DJ, Levesque MP, Besser MJ, Schachter J, Golani O, Segal E, Geva-Zatorsky N, Ruppin E, Kvistborg P, Peterson SN, Wargo JA, Straussman R, Samuels Y, Galloway-Pe?a JR. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021 04; 592(7852):138-143. PMID: 33731925; PMCID: PMC9717498.
      Citations: 37     Fields:    Translation:HumansCells
    99. El Alam MB, Sims TT, Kouzy R, Biegert GWG, Jaoude JABI, Karpinets TV, Yoshida-Court K, Wu X, Delgado-Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021; 16(3):e0247905. PMID: 33662003; PMCID: PMC7932122.
      Citations: 2     Fields:    Translation:HumansCells
    100. Sims TT, El Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, Yoshida-Court K, Wu X, Biegert GWG, Delgado Medrano AY, Solley T, Ahmed-Kaddar M, Chapman BV, Sastry KJ, Mezzari MP, Petrosino JF, Lin LL, Ramondetta L, Jhingran A, Schmeler KM, Ajami NJ, Wargo J, Colbert LE, Klopp AH. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 02 22; 4(1):237. PMID: 33619320; PMCID: PMC7900251.
      Citations: 17     Translation:HumansCells
    101. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514. PMID: 33603241; PMCID: PMC8818318.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    102. Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 02; 27(2):301-309. PMID: 33558722.
      Citations: 44     Fields:    Translation:Humans
    103. Sweeney KJ, Tetzlaff MT, Vega F, Gillenwater A, Zuo Z, Gross N, Nagarajan P, Wargo J, Nelson K, Prieto VG, Torres-Cabala CA, Curry JL. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. J Cutan Pathol. 2021 May; 48(5):674-679. PMID: 33399228.
      Citations:    Fields:    Translation:HumansCells
    104. Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M, Beqiri M, Kiernan M, Perego M, Wang F, Xiao M, Brafford P, Yang X, Xu X, Secreto A, Danet-Desnoyers G, Traum D, Kaestner KH, Huang AC, Hristova D, Wang J, Fukunaga-Kalabis M, Krepler C, Ping-Chen F, Zhou X, Gutierrez A, Rebecca VW, Vonteddu P, Dotiwala F, Bala S, Majumdar S, Dweep H, Wickramasinghe J, Kossenkov AV, Reyes-Arbujas J, Santiago K, Nguyen T, Griss J, Keeney F, Hayden J, Gavin BJ, Weiner D, Montaner LJ, Liu Q, Peiffer L, Burton EM, Davies MA, Tetzlaff MT, Muthumani K, Wargo JA, Gabrilovich D, Herlyn M, Becker J. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021 01 12; 12(1):346. PMID: 33436641; PMCID: PMC7804257.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    105. Jiang W, Wang Y, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol. 2021 01; 16(1):6-15. PMID: 33349682; PMCID: PMC8103921.
      Citations: 9     Fields:    Translation:HumansAnimals
    106. Bartok O, Pataskar A, Nagel R, Laos M, Goldfarb E, Hayoun D, Levy R, Kreuger IZM, Champagne J, Zaal EA, Bleijerveld OB, Huang X, Kenski J, Wargo J, Brandis A, Levin Y, Mizrahi O, Alon M, Lebon S, Yang W, Nielsen MM, Stern-Ginossar N, Altelaar M, Berkers CR, Geiger T, Peeper DS, Olweus J, Samuels Y, Agami R, K?rner PR. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature. 2021 02; 590(7845):332-337. PMID: 33328638.
      Citations: 16     Fields:    Translation:HumansCells
    107. Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021 02 05; 371(6529):602-609. PMID: 33303685.
      Citations: 166     Fields:    Translation:HumansCellsCTClinical Trials
    108. Mueller KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, Ariyan CE, Atkins MB, Berry DA, Blank CU, DeMichele AM, Forde PM, Ibrahim N, Keegan P, Mitchell TC, Moss RA, Robert C, Sridhara R, Taube JM, Tetzlaff MT, Wargo JA, Flaherty KT, Kaplan MJ, Topalian SL, Ward AF, Hurlbert MS. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. Clin Cancer Res. 2021 01 15; 27(2):394-401. PMID: 33188142.
      Citations: 2     Fields:    Translation:Humans
    109. White MG, Wargo JA. Gut Microbes' Impact on Oncogenic Drivers: Location Matters. Mol Cell. 2020 09 17; 79(6):878-880. PMID: 32946762; PMCID: PMC7717102.
      Citations:    Fields:    Translation:Humans
    110. Wargo JA. Modulating gut microbes. Science. 2020 09 11; 369(6509):1302-1303. PMID: 32913089.
      Citations: 22     Fields:    Translation:HumansCells
    111. Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang ZQ, Reuben A, Cooper ZA, Ivan C, Ju Z, Nwajei F, Wang J, Davies MA, Davis RE, Wargo JA, Bhattacharya PK, Hong DS, Curran MA. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. 2020 11; 8(11):1365-1380. PMID: 32917656; PMCID: PMC7642111.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    112. Manzo T, Prentice BM, Anderson KG, Raman A, Schalck A, Codreanu GS, Nava Lauson CB, Tiberti S, Raimondi A, Jones MA, Reyzer M, Bates BM, Spraggins JM, Patterson NH, McLean JA, Rai K, Tacchetti C, Tucci S, Wargo JA, Rodighiero S, Clise-Dwyer K, Sherrod SD, Kim M, Navin NE, Caprioli RM, Greenberg PD, Draetta G, Nezi L. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med. 2020 08 03; 217(8). PMID: 32491160; PMCID: PMC7398173.
      Citations: 30     Fields:    Translation:AnimalsCells
    113. Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020 11; 31(11):1569-1579. PMID: 32739408.
      Citations: 3     Fields:    Translation:Humans
    114. Finlay BB, Honda K, Trinchieri G, Wargo J, Goldszmid R, Zitvogel L. Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol. 2020 09; 20(9):522-528. PMID: 32661409.
      Citations: 22     Fields:    Translation:HumansAnimals
    115. McQuade JL, Ologun GO, Arora R, Wargo JA. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Curr Oncol Rep. 2020 06 24; 22(7):74. PMID: 32577835; PMCID: PMC7685568.
      Citations: 13     Fields:    Translation:Humans
    116. Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA, Galloway-Pe?a JR. Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis. 2020 06 24; 71(1):63-71. PMID: 31436833; PMCID: PMC7312220.
      Citations: 27     Fields:    Translation:Humans
    117. Fang S, Lu J, Zhou X, Wang Y, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Sui D, Amos CI, Lee JE. Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis. 2020 06 17; 41(4):452-457. PMID: 31630191; PMCID: PMC7298620.
      Citations: 1     Fields:    Translation:Humans
    118. Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020 05 29; 368(6494):973-980. PMID: 32467386; PMCID: PMC7757858.
      Citations: 267     Fields:    Translation:HumansCells
    119. Halsey T, Ologun G, Wargo J, Jenq RR. Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review. Semin Hematol. 2020 01; 57(1):13-18. PMID: 32690139; PMCID: PMC7391470.
      Citations: 4     Fields:    Translation:HumansAnimals
    120. Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Tetzlaff MT, Becker JC. T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. J Invest Dermatol. 2020 11; 140(11):2146-2156.e4. PMID: 32304704.
      Citations: 5     Fields:    Translation:HumansCells
    121. Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839. PMID: 32296058; PMCID: PMC7160105.
      Citations: 5     Fields:    Translation:Humans
    122. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, van Schoiack A, Warren S, Pietras K, Schadendorf D, Bastholt L, Carneiro A, Wargo JA, Svane IM, L?vgren K, Jirstr?m K, Olsson H, Ingvar C, Isaksson K, Schmidt H, J?nsson G. Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020 04; 580(7801):E1. PMID: 32238929.
      Citations: 12     Fields:    
    123. Ajami NJ, Wargo JA. AI finds microbial signatures in tumours and blood across cancer types. Nature. 2020 03; 579(7800):502-503. PMID: 32161344.
      Citations: 3     Fields:    Translation:Humans
    124. Khan MAW, Ologun G, Arora R, McQuade JL, Wargo JA. Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 03; 65(3):885-896. PMID: 32067144; PMCID: PMC7678709.
      Citations: 11     Fields:    Translation:HumansAnimals
    125. Galvani E, Mundra PA, Valpione S, Garcia-Martinez P, Smith M, Greenall J, Thakur R, Helmink B, Andrews MC, Boon L, Chester C, Gremel G, Hogan K, Mandal A, Zeng K, Banyard A, Ashton G, Cook M, Lorigan P, Wargo JA, Dhomen N, Marais R. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nat Commun. 2020 02 12; 11(1):853. PMID: 32051401; PMCID: PMC7015935.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    126. Xavier JB, Young VB, Skufca J, Ginty F, Testerman T, Pearson AT, Macklin P, Mitchell A, Shmulevich I, Xie L, Caporaso JG, Crandall KA, Simone NL, Godoy-Vitorino F, Griffin TJ, Whiteson KL, Gustafson HH, Slade DJ, Schmidt TM, Walther-Antonio MRS, Korem T, Webb-Robertson BM, Styczynski MP, Johnson WE, Jobin C, Ridlon JM, Koh AY, Yu M, Kelly L, Wargo JA. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer. 2020 03; 6(3):192-204. PMID: 32101723; PMCID: PMC7098063.
      Citations: 57     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    127. Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895. PMID: 32015020.
      Citations: 14     Fields:    Translation:HumansCells
    128. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603. PMID: 32001676; PMCID: PMC6992630.
      Citations: 54     Fields:    Translation:HumansCells
    129. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441. PMID: 31990608; PMCID: PMC7193747.
      Citations: 5     Fields:    Translation:Humans
    130. Helmink BA, Roland CL, Kiernan CM, Wargo JA. Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Ann Surg Oncol. 2020 May; 27(5):1533-1545. PMID: 31965370; PMCID: PMC7594106.
      Citations: 1     Fields:    Translation:Humans
    131. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, van Schoiack A, Warren S, Pietras K, Schadendorf D, Bastholt L, Carneiro A, Wargo JA, Svane IM, L?vgren K, Jirstr?m K, Olsson H, Ingvar C, Isaksson K, Schmidt H, J?nsson G. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020 01; 577(7791):561-565. PMID: 31942071.
      Citations: 426     Fields:    Translation:HumansCells
    132. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA, Saut?s-Fridman C. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555. PMID: 31942075; PMCID: PMC8762581.
      Citations: 512     Fields:    Translation:HumansCells
    133. Petitprez F, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Moreira M, Lacroix G, Natario I, Adam J, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Tawbi HA, Fridman WH, de Reyni?s A, Bougo?in A, Lucchesi C, Laizet YH, Toulmonde M, Italiano A, Saut?s-Fridman C. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020 01; 577(7791):556-560. PMID: 31942077.
      Citations: 441     Fields:    Translation:HumansCells
    134. Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, Wang WL, Wargo JA, Tawbi HA. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020 03 15; 26(6):1258-1266. PMID: 31900276; PMCID: PMC7731262.
      Citations: 49     Fields:    Translation:HumansCellsCTClinical Trials
    135. Toker J, Arora R, Wargo JA. The Microbiome in Immuno-oncology. Adv Exp Med Biol. 2020; 1244:325-334. PMID: 32301026.
      Citations: 4     Fields:    Translation:Humans
    136. McAllister F, Khan MAW, Helmink B, Wargo JA. The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond. Cancer Cell. 2019 12 09; 36(6):577-579. PMID: 31951558.
      Citations: 20     Fields:    Translation:HumansCells
    137. Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 Nov; 20(11):1555. PMID: 31551574.
      Citations: 3     Fields:    
    138. Tang C, Lee WC, Reuben A, Chang L, Tran H, Little L, Gumbs C, Wargo J, Futreal A, Liao Z, Xia X, Yi X, Swisher SG, Heymach JV, Gomez D, Zhang J. Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. Int J Radiat Oncol Biol Phys. 2020 02 01; 106(2):349-357. PMID: 31678224.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    139. Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019 11 05; 116(45):22699-22709. PMID: 31636208; PMCID: PMC6842624.
      Citations: 93     Fields:    Translation:AnimalsCells
    140. Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251. PMID: 31611368; PMCID: PMC6825284.
      Citations: 50     Fields:    Translation:Humans
    141. Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Ferrere G, Becharef S, Messaoudene M, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Gaudreau PO, Gopalakrishnan V, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Bronte V, Wargo J, Zitvogel L, Verlingue L, V?tizou M, Daill?re R, Enot DP, Marabelle A, Prevost-Blondel A, Eggermont AM, Opolon P, Soria JC, Kroemer G. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019 Oct; 29(10):846-861. PMID: 31481761; PMCID: PMC6796942.
      Citations: 68     Fields:    Translation:HumansAnimalsCells
    142. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jenq R, Wargo J, McAllister F. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12. PMID: 31398337; PMCID: PMC7288240.
      Citations: 280     Fields:    Translation:HumansAnimalsCells
    143. Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513. PMID: 31383963.
      Citations: 4     Fields:    Translation:Humans
    144. Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 09; 20(9):1231-1243. PMID: 31358999; PMCID: PMC7472661.
      Citations: 93     Fields:    Translation:HumansAnimalsCells
    145. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389. PMID: 31267972.
      Citations: 47     Fields:    Translation:Humans
    146. Keung EZ, Wargo JA. The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surg Oncol Clin N Am. 2019 07; 28(3):369-386. PMID: 31079794.
      Citations: 7     Fields:    Translation:HumansAnimals
    147. Elinav E, Garrett WS, Trinchieri G, Wargo J. The cancer microbiome. Nat Rev Cancer. 2019 07; 19(7):371-376. PMID: 31186547; PMCID: PMC6700740.
      Citations: 59     Fields:    Translation:Humans
    148. Fang S, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, Wargo J, Sui D, Wei Q, Amos CI, Lee JE. Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. J Invest Dermatol. 2019 11; 139(11):2352-2358.e3. PMID: 31176707; PMCID: PMC6814532.
      Citations: 13     Fields:    Translation:HumansCells
    149. Helmink B, Wargo JA. Neoadjuvant therapy for melanoma: is it ready for prime time? Lancet Oncol. 2019 07; 20(7):892-894. PMID: 31171445.
      Citations: 3     Fields:    Translation:Humans
    150. Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470. PMID: 31160495; PMCID: PMC6662573.
      Citations: 22     Fields:    Translation:HumansCells
    151. Mauzo SH, Tetzlaff MT, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP, Milton DR. Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. Cancers (Basel). 2019 May 29; 11(6). PMID: 31146499; PMCID: PMC6627796.
      Citations: 10     
    152. Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunol Res. 2019 06; 7(6):1025-1035. PMID: 31043414; PMCID: PMC7053657.
      Citations: 28     Fields:    Translation:HumansCells
    153. Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT, Milton DR. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. 2019 Sep; 46(9):627-636. PMID: 30883858.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    154. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019 03; 25(3):377-388. PMID: 30842679.
      Citations: 222     Fields:    Translation:Humans
    155. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res. 2019 06 01; 25(11):3455-3467. PMID: 30808776; PMCID: PMC8211110.
      Citations: 9     Fields:    Translation:HumansCells
    156. Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA, de Macedo MP. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645. PMID: 30787016; PMCID: PMC6497554.
      Citations: 87     Fields:    Translation:HumansAnimalsCells
    157. McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019 02; 20(2):e77-e91. PMID: 30712808.
      Citations: 89     Fields:    Translation:Humans
    158. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697. PMID: 30635425; PMCID: PMC6358697.
      Citations: 115     Fields:    Translation:HumansCells
    159. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N, Villani AC. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019 Jan 10; 176(1-2):404. PMID: 30633907; PMCID: PMC6647017.
      Citations: 67     Fields:    
    160. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2019 Jan; 25(1):188. PMID: 30479380.
      Citations: 2     Fields:    
    161. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA, Milton DR. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941. PMID: 30361510.
      Citations:    Fields:    
    162. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA, Milton DR. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942. PMID: 30361511.
      Citations: 5     Fields:    
    163. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808. PMID: 30420754; PMCID: PMC6322556.
      Citations: 183     Fields:    Translation:HumansCells
    164. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N, Villani AC. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 11 01; 175(4):998-1013.e20. PMID: 30388456; PMCID: PMC6641984.
      Citations: 430     Fields:    Translation:HumansAnimalsCells
    165. Cogdill AP, Gaudreau PO, Arora R, Gopalakrishnan V, Wargo JA. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol. 2018 11; 39(11):900-920. PMID: 30392721.
      Citations: 16     Fields:    Translation:HumansAnimals
    166. Smith MP, Rana S, Ferguson J, Rowling EJ, Flaherty KT, Wargo JA, Marais R, Wellbrock C. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma. Pigment Cell Melanoma Res. 2019 03; 32(2):280-291. PMID: 30277012; PMCID: PMC6392120.
      Citations: 15     Fields:    Translation:HumansCells
    167. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA, Milton DR. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654. PMID: 30297909; PMCID: PMC6481682.
      Citations: 220     Fields:    Translation:HumansCTClinical Trials
    168. Kaur A, Ecker BL, Douglass SM, Kugel CH, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, Weeraratna AT. Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov. 2019 01; 9(1):64-81. PMID: 30279173; PMCID: PMC6328333.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    169. Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018 Sep 24; 18(1):913. PMID: 30249211; PMCID: PMC6154892.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    170. Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y, Forget MA. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discov. 2018 11; 8(11):1366-1375. PMID: 30209080; PMCID: PMC6453138.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    171. Farah M, Nagarajan P, Curry JL, Tang Z, Kim TB, Aung PP, Torres-Cabala CA, Eterovic AK, Wargo JA, Prieto VG, Tetzlaff MT. Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia. Br J Dermatol. 2019 02; 180(2):404-408. PMID: 29897634.
      Citations: 3     Fields:    Translation:Humans
    172. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 08 01; 29(8):1861-1868. PMID: 29945191; PMCID: PMC6096739.
      Citations: 35     Fields:    Translation:Humans
    173. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 02 15; 25(4):1233-1238. PMID: 30054281; PMCID: PMC6348141.
      Citations: 114     Fields:    Translation:HumansCells
    174. Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B, Tetzlaff MT. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. Oncoimmunology. 2018; 7(9):e1475874. PMID: 30228943; PMCID: PMC6140585.
      Citations: 4     Fields:    
    175. Helmink BA, Gaudreau PO, Wargo JA. Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity. 2018 06 19; 48(6):1077-1080. PMID: 29924973.
      Citations: 11     Fields:    Translation:Humans
    176. Routy B, Gopalakrishnan V, Zitvogel L, Wargo JA, Kroemer G, Daill?re R. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018 06; 15(6):382-396. PMID: 29636538.
      Citations: 147     Fields:    Translation:HumansCells
    177. Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C, Forget MA, Tavera RJ. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428. PMID: 29848573; PMCID: PMC6139043.
      Citations: 43     Fields:    Translation:HumansCells
    178. Eggermont AMM, Crittenden M, Wargo J. Combination Immunotherapy Development in Melanoma. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:197-207. PMID: 30231333.
      Citations: 23     Fields:    Translation:Humans
    179. Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol. 2018 Jul; 45(7):545-549. PMID: 29672900.
      Citations: 2     Fields:    Translation:HumansCells
    180. Andrews MC, Reuben A, Gopalakrishnan V, Wargo JA. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Front Immunol. 2018; 9:946. PMID: 29780391; PMCID: PMC5945998.
      Citations: 9     Fields:    Translation:HumansAnimals
    181. Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell. 2018 04 09; 33(4):570-580. PMID: 29634945; PMCID: PMC6529202.
      Citations: 335     Fields:    Translation:HumansCells
    182. Karpinets TV, Gopalakrishnan V, Wargo J, Futreal AP, Schadt CW, Zhang J. Linking Associations of Rare Low-Abundance Species to Their Environments by Association Networks. Front Microbiol. 2018; 9:297. PMID: 29563898; PMCID: PMC5850922.
      Citations: 5     
    183. Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol. 2018 Jul; 25(7):1814-1827. PMID: 29500764; PMCID: PMC6105272.
      Citations: 20     Fields:    Translation:Humans
    184. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567. PMID: 29496665; PMCID: PMC5932238.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    185. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Woodman SE, Hwu P, Forget MA, Liz?e G. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376. PMID: 29496759; PMCID: PMC9872773.
      Citations: 28     Fields:    Translation:HumansCells
    186. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322. PMID: 29449192; PMCID: PMC5840029.
      Citations: 203     Fields:    Translation:Humans
    187. Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018 02 12; 6(1):14. PMID: 29433571; PMCID: PMC5810034.
      Citations: 39     Fields:    Translation:Humans
    188. Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 2018; 7(5):e1423172. PMID: 29721378; PMCID: PMC5927481.
      Citations: 12     Fields:    
    189. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193. PMID: 29361468.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    190. Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M, Garbe C. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med. 2017 11 16; 15(1):236. PMID: 29145885; PMCID: PMC5691855.
      Citations: 11     Fields:    Translation:HumansCells
    191. Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, Hoon D, Karakousis G, Liu Q, Mitra N, Petrelli NJ, Schuchter L, Shannan B, Shields CL, Wargo J, Wenz B, Wilson MA, Xiao M, Xu W, Xu X, Yin X, Zhang NR, Davies MA, Herlyn M, Nathanson KL. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep. 2017 Nov 14; 21(7):1936-1952. PMID: 29141224; PMCID: PMC5709812.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    192. Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep. 2017 Nov 14; 21(7):1953-1967. PMID: 29141225; PMCID: PMC5726788.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    193. Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA. The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med. 2017 11 03; 15(1):223. PMID: 29100546; PMCID: PMC5670700.
      Citations: 11     Fields:    Translation:Humans
    194. Andrews MC, Wargo JA. Cancer Evolution during Immunotherapy. Cell. 2017 11 02; 171(4):740-742. PMID: 29100071; PMCID: PMC5755374.
      Citations:    
    195. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA, Zitvogel L. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103. PMID: 29097493; PMCID: PMC5827966.
      Citations: 1227     Fields:    Translation:HumansAnimals
    196. Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018; 7(2):e1385689. PMID: 29308306; PMCID: PMC5749668.
      Citations: 19     Fields:    
    197. Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN, Hafner C, Mayerh?fer M. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun. 2017 09 19; 8(1):607. PMID: 28928360; PMCID: PMC5605714.
      Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
    198. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 09 15; 357(6356):1156-1160. PMID: 28912244; PMCID: PMC5727343.
      Citations: 349     Fields:    Translation:HumansAnimalsCells
    199. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 Sep 07; 170(6):1120-1133.e17. PMID: 28803728; PMCID: PMC5591072.
      Citations: 443     Fields:    Translation:HumansAnimalsCells
    200. Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology. 2017; 6(12):e1361097. PMID: 29209563; PMCID: PMC5706622.
      Citations: 19     Fields:    
    201. Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C, Kmarashev J, Levesque MP, Dummer R. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. 2017 08; 9(8):1011-1029. PMID: 28606996; PMCID: PMC5538298.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    202. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J, Forget MA. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097. PMID: 28733428; PMCID: PMC5628137.
      Citations: 67     Fields:    Translation:Humans
    203. Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A, Wargo JA. Interaction of molecular alterations with immune response in melanoma. Cancer. 2017 06 01; 123(S11):2130-2142. PMID: 28543700; PMCID: PMC6105277.
      Citations: 10     Fields:    Translation:HumansCells
    204. Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017 Jun 27; 117(1):1-7. PMID: 28524159; PMCID: PMC5520201.
      Citations: 85     Fields:    Translation:HumansCells
    205. Qin Y, Petaccia de Macedo M, Reuben A, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP, Forget MA. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology. 2017; 6(6):e1321187. PMID: 28680759; PMCID: PMC5486182.
      Citations: 21     Fields:    
    206. Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov. 2017 08; 7(8):832-851. PMID: 28455392; PMCID: PMC5540806.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    207. Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A, Kamarashev J. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med. 2017 06 05; 214(6):1691-1710. PMID: 28450382; PMCID: PMC5460994.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    208. Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher DE. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res. 2017 Aug 15; 23(16):4680-4692. PMID: 28446504; PMCID: PMC5559310.
      Citations: 3     Fields:    Translation:HumansAnimals
    209. Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795. PMID: 28442307.
      Citations: 22     Fields:    Translation:Humans
    210. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA, Forget MA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2. PMID: 28819565; PMCID: PMC5557036.
      Citations: 64     
    211. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555. PMID: 28346412; PMCID: PMC5466900.
      Citations: 199     Fields:    Translation:HumansAnimalsCells
    212. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379). PMID: 28251903; PMCID: PMC5819607.
      Citations: 323     Fields:    Translation:HumansCells
    213. Andrews MC, Wargo JA. Immunotherapy resistance: the answers lie ahead - not in front - of us. J Immunother Cancer. 2017; 5:10. PMID: 28239464; PMCID: PMC5319188.
      Citations: 6     Fields:    Translation:Humans
    214. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017 02 09; 168(4):707-723. PMID: 28187290; PMCID: PMC5391692.
      Citations: 1406     Fields:    Translation:HumansAnimalsCells
    215. Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176. PMID: 27859479.
      Citations: 51     Fields:    Translation:Humans
    216. Gee MS, Ghazani AA, Haq R, Wargo JA, Sebas M, Sullivan RJ, Lee H, Weissleder R. Point of care assessment of melanoma tumor signaling and metastatic burden from ?NMR analysis of tumor fine needle aspirates and peripheral blood. Nanomedicine. 2017 04; 13(3):821-828. PMID: 27993725; PMCID: PMC5392428.
      Citations: 2     Fields:    Translation:HumansCells
    217. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381. PMID: 27911979; PMCID: PMC5384865.
      Citations: 18     Fields:    Translation:Humans
    218. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M, Dummer R, Garbe C. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313. PMID: 27846884; PMCID: PMC5111349.
      Citations: 6     Fields:    Translation:HumansAnimals
    219. Cogdill AP, Prieto PA, Reuben A, Wargo JA. Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper? Clin Cancer Res. 2017 Jan 15; 23(2):327-329. PMID: 27836861; PMCID: PMC5241203.
      Citations: 1     Fields:    Translation:Humans
    220. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE, Forget MA. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168. PMID: 27776519; PMCID: PMC5078889.
      Citations: 64     Fields:    Translation:HumansCells
    221. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9. PMID: 27667683; PMCID: PMC5088716.
      Citations: 475     Fields:    Translation:HumansAnimalsCells
    222. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA, Jan?-Valbuena J. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64. PMID: 27124486; PMCID: PMC4982774.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    223. Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther. 2016 10; 15(10):2442-2454. PMID: 27458138; PMCID: PMC5079683.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    224. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Sep 08; 537(7619):254. PMID: 27383789.
      Citations: 6     Fields:    
    225. Reddy SM, Reuben A, Wargo JA. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr Oncol Rep. 2016 07; 18(7):42. PMID: 27215436; PMCID: PMC5330383.
      Citations: 23     Fields:    Translation:Humans
    226. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37. PMID: 27301722; PMCID: PMC5082984.
      Citations: 385     Fields:    Translation:HumansCells
    227. Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol. 2016 08; 41:23-31. PMID: 27240055; PMCID: PMC5257261.
      Citations: 49     Fields:    Translation:Humans
    228. Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL, Torres-Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5553-5563. PMID: 27166398; PMCID: PMC5857157.
      Citations: 42     Fields:    Translation:HumansCells
    229. Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA, Galloway-Pe?a JR. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016 07 15; 122(14):2186-96. PMID: 27142181; PMCID: PMC5574182.
      Citations: 56     Fields:    Translation:Humans
    230. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA, Dummer R. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16. PMID: 27087480; PMCID: PMC5228487.
      Citations: 37     Fields:    Translation:HumansCells
    231. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. 2016 05 02; 126(5):1834-56. PMID: 27043285; PMCID: PMC4855947.
      Citations: 127     Fields:    Translation:HumansAnimalsCells
    232. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4. PMID: 27042933; PMCID: PMC4833579.
      Citations: 136     Fields:    Translation:HumansAnimalsCells
    233. Villani V, Mahadevan KK, Ligorio M, Ting DT, Sabbatino F, Zhang I, Vangel M, Ferrone S, Warshaw AL, Lillemoe KD, Wargo J, Deshpande V, Ferrone CR, Fern?ndez-Del Castillo C. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2016 12; 23(Suppl 5):609-617. PMID: 27020585; PMCID: PMC8713440.
      Citations: 12     Fields:    Translation:HumansCells
    234. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7. PMID: 27001565; PMCID: PMC4966337.
      Citations: 28     Fields:    Translation:Humans
    235. Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 2016 08 01; 122(15):2299-312. PMID: 26991400; PMCID: PMC5567680.
      Citations: 100     Fields:    Translation:Humans
    236. Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C, Levesque MP, Dummer R. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 2016 Mar 14; 29(3):270-284. PMID: 26977879; PMCID: PMC4796027.
      Citations: 93     Fields:    Translation:HumansCells
    237. Reuben A, Cooper ZA, Wargo JA, Prieto PA. Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J. 2016 Mar-Apr; 22(2):138-46. PMID: 27111910; PMCID: PMC6478395.
      Citations: 20     Fields:    Translation:HumansAnimals
    238. Hu Z, Xia J, Fan W, Wargo J, Yang YG. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. Oncotarget. 2016 Feb 09; 7(6):6448-59. PMID: 26824989; PMCID: PMC4872726.
      Citations: 25     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    239. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044. PMID: 27141370; PMCID: PMC4839346.
      Citations: 27     Fields:    
    240. Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Liz?e G. Novel Treatments in Development for Melanoma. Cancer Treat Res. 2016; 167:371-416. PMID: 26601872.
      Citations: 7     Fields:    Translation:HumansCells
    241. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P, Liz?e G. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16. PMID: 26645196; PMCID: PMC4744499.
      Citations: 581     Fields:    Translation:HumansAnimalsCells
    242. Reuben A, Gopalakrishnan V, Wagner HE, Spencer CN, Austin-Breneman J, Jiang H, Cooper ZA, Wargo JA. Working with Human Tissues for Translational Cancer Research. J Vis Exp. 2015 Nov 26; (105). PMID: 26649748; PMCID: PMC4692755.
      Citations:    Fields:    
    243. Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP, Galloway-Pe?a J. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One. 2015; 10(11):e0139851. PMID: 26556047; PMCID: PMC4640583.
      Citations: 23     Fields:    Translation:HumansAnimals
    244. Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2015; 10(10):e0140310. PMID: 26461489; PMCID: PMC4604168.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    245. Reuben A, Austin-Breneman J, Wargo JA, Cooper ZA. Raising the bar: optimizing combinations of targeted therapy and immunotherapy. Ann Transl Med. 2015 Oct; 3(18):272. PMID: 26605318; PMCID: PMC4630548.
      Citations:    
    246. Chin L, Wargo JA, Spring DJ, Kantarjian H, Futreal PA. Cancer Genomics in Clinical Context. Trends Cancer. 2015 Sep; 1(1):36-43. PMID: 28741560.
      Citations: 5     Fields:    
    247. Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KSM. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol. 2015 Dec; 135(12):3115-3124. PMID: 26302068; PMCID: PMC4648653.
      Citations: 42     Fields:    Translation:HumansCells
    248. Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016 Mar 10; 35(10):1225-35. PMID: 26073081; PMCID: PMC4679729.
      Citations:    
    249. Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ. Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol. 2015 Aug; 42(4):601-16. PMID: 26320064; PMCID: PMC4955940.
      Citations: 59     Fields:    Translation:Humans
    250. Cooper ZA, Reuben A, Austin-Breneman J, Wargo JA. Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clin Cancer Res. 2015 Jul 15; 21(14):3102-4. PMID: 26025561; PMCID: PMC4506225.
      Citations: 11     Fields:    Translation:HumansCells
    251. Kim H, Frederick DT, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Flaherty KT, Ronai ZA, Levesque MP, Dummer R. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep. 2015 Jun 09; 11(9):1458-73. PMID: 26027934; PMCID: PMC4681438.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    252. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10. PMID: 26058727; PMCID: PMC4515190.
      Citations: 13     Fields:    Translation:Humans
    253. Amaria RN, Reuben A, Cooper ZA, Wargo JA. Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther. 2015; 4:79-89. PMID: 27471714; PMCID: PMC4918260.
      Citations: 9     
    254. Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17. PMID: 25754356.
      Citations: 6     Fields:    Translation:HumansCells
    255. Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Tsao H, J?nsson G. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015 Jul; 135(7):1863-1872. PMID: 25789707; PMCID: PMC4466007.
      Citations: 37     Fields:    Translation:HumansCells
    256. Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70. PMID: 25705882; PMCID: PMC4396463.
      Citations: 66     Fields:    Translation:HumansAnimals
    257. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG, Ramirez JL, Mu?oz-Couselo E. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6. PMID: 25665005; PMCID: PMC4930244.
      Citations: 224     Fields:    Translation:HumansAnimalsCells
    258. Flaherty KT, Wargo JA, Bivona TG. YAP in MAPK pathway targeted therapy resistance. Cell Cycle. 2015; 14(12):1765-6. PMID: 26036142; PMCID: PMC4612653.
      Citations: 9     Fields:    Translation:HumansAnimals
    259. Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87. PMID: 25542448; PMCID: PMC4355085.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    260. Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 12 23; 7(357):ra121. PMID: 25538079; PMCID: PMC4353587.
      Citations: 84     Fields:    Translation:HumansAnimalsCells
    261. Cooper ZA, Reuben A, Amaria RN, Wargo JA. Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology. 2014 Oct; 3(9):e954956. PMID: 25941608; PMCID: PMC4292518.
      Citations: 11     Fields:    
    262. Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med. 2014 Dec; 11(4):237-46. PMID: 25610709; PMCID: PMC4296084.
      Citations: 40     Fields:    
    263. Wargo JA, Cooper ZA, Flaherty KT. Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov. 2014 Dec; 4(12):1377-86. PMID: 25395294; PMCID: PMC4258160.
      Citations: 35     Fields:    Translation:HumansAnimals
    264. Reuben A, Amaria RN, Cooper ZA, Wargo JA. RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. J Pigment Disord. 2014 Nov; 1(5). PMID: 29250602; PMCID: PMC5731654.
      Citations:    
    265. Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8. PMID: 25319388; PMCID: PMC4258469.
      Citations: 11     Fields:    Translation:HumansCells
    266. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma. Cancer Res. 2014 Dec 01; 74(23):7037-47. PMID: 25297634; PMCID: PMC4347853.
      Citations: 94     Fields:    Translation:HumansCells
    267. Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFa. Cancer Discov. 2014 Oct; 4(10):1214-1229. PMID: 25256614; PMCID: PMC4184867.
      Citations: 103     Fields:    Translation:HumansAnimalsCells
    268. Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31. PMID: 25252955; PMCID: PMC4201984.
      Citations: 63     Fields:    Translation:AnimalsCells
    269. Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N. Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer Immunol Res. 2014 Aug; 2(8):714-9. PMID: 25092813.
      Citations: 13     Fields:    Translation:Humans
    270. Konstantinidis IT, Kambadakone A, Catalano OA, Sahani DV, Deshpande V, Forcione DG, Wargo JA, Fernandez-Del Castillo C, Lillemoe KD, Warshaw AL, Ferrone CR. Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. World J Gastrointest Surg. 2014 Jul 27; 6(7):136-41. PMID: 25068011; PMCID: PMC4110531.
      Citations: 1     
    271. Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286. PMID: 24983357; PMCID: PMC4077767.
      Citations: 25     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    272. Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, Parangi S. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid. 2014 Aug; 24(8):1241-50. PMID: 24811699; PMCID: PMC4106380.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    273. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54. PMID: 24903021; PMCID: PMC4097121.
      Citations: 118     Fields:    Translation:HumansAnimalsCells
    274. Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27. PMID: 24771846; PMCID: PMC4154497.
      Citations: 239     Fields:    Translation:HumansCells
    275. Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41. PMID: 24732172; PMCID: PMC4039118.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    276. Fernandez-del Castillo CF, Thayer SP, Ferrone CR, Wargo J. Surgery for small and asymptomatic branch-duct IPMNs. Ann Surg. 2014 Mar; 259(3):e47. PMID: 24096750.
      Citations: 3     Fields:    Translation:Humans
    277. Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery. 2013 Dec; 154(6):1456-62; discussion 1462. PMID: 24238058; PMCID: PMC3863391.
      Citations: 7     Fields:    Translation:HumansCells
    278. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8. PMID: 24265154; PMCID: PMC3947296.
      Citations: 237     Fields:    Translation:HumansCellsCTClinical Trials
    279. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013 Dec 05; 504(7478):138-42. PMID: 24185007; PMCID: PMC4098832.
      Citations: 239     Fields:    Translation:HumansCells
    280. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013 Dec; 3(12):1378-93. PMID: 24104062; PMCID: PMC3918498.
      Citations: 105     Fields:    Translation:HumansAnimalsCells
    281. Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2013 Oct 01; 2(10):e26615. PMID: 24251082; PMCID: PMC3827093.
      Citations: 48     Fields:    
    282. Fong ZV, Ferrone CR, Thayer SP, Wargo JA, Sahora K, Seefeld KJ, Warshaw AL, Lillemoe KD, Hutter MM, Fern?ndez-Del Castillo C. Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. J Gastrointest Surg. 2014 Jan; 18(1):137-44; discussion 144-5. PMID: 24002770.
      Citations: 30     Fields:    Translation:Humans
    283. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98. PMID: 23903755; PMCID: PMC3867020.
      Citations: 81     Fields:    Translation:HumansAnimalsCells
    284. Sullivan RJ, Lawrence DP, Wargo JA, Oh KS, Gonzalez RG, Piris A. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med. 2013 Jul 11; 369(2):173-83. PMID: 23841733.
      Citations: 11     Fields:    Translation:HumansCells
    285. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8. PMID: 23657686; PMCID: PMC3662845.
      Citations: 115     Fields:    Translation:Humans
    286. Cooper ZA, Frederick DT, Ahmed Z, Wargo JA. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology. 2013 May 01; 2(5):e24320. PMID: 23762807; PMCID: PMC3667913.
      Citations: 25     Fields:    
    287. Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013 Apr; 257(4):731-6. PMID: 22968073.
      Citations: 125     Fields:    Translation:Humans
    288. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR. Oncogenic BRAF regulates oxidative metabolism via PGC1a and MITF. Cancer Cell. 2013 Mar 18; 23(3):302-15. PMID: 23477830; PMCID: PMC3635826.
      Citations: 382     Fields:    Translation:HumansCells
    289. Haq R, Yokoyama S, Hawryluk EB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE, J?nsson GB. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4321-6. PMID: 23447565; PMCID: PMC3600451.
      Citations: 110     Fields:    Translation:HumansCells
    290. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA, Liz?e G. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31. PMID: 23307859; PMCID: PMC3752683.
      Citations: 404     Fields:    Translation:HumansCells
    291. Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD, Warshaw AL, Thayer SP, Fern?ndez-del Castillo C. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013 Feb; 17(2):257-66. PMID: 23229885; PMCID: PMC3806050.
      Citations: 46     Fields:    Translation:Humans
    292. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Hwu P, Liz?e G. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403. PMID: 23204132; PMCID: PMC4120472.
      Citations: 167     Fields:    Translation:HumansAnimalsCells
    293. Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K, Maertens O. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013 Mar; 3(3):338-49. PMID: 23171796; PMCID: PMC3595355.
      Citations: 107     Fields:    Translation:HumansAnimalsCells
    294. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012 Nov 15; 491(7424):449-53. PMID: 23123854; PMCID: PMC3521494.
      Citations: 160     Fields:    Translation:AnimalsCells
    295. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013 Feb 01; 19(3):598-609. PMID: 23095323.
      Citations: 209     Fields:    Translation:HumansCells
    296. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Oct; 18(10):1503-10. PMID: 22983396; PMCID: PMC3777533.
      Citations: 174     Fields:    Translation:HumansAnimalsCells
    297. Khalili JS, Liu S, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Rodr?guez-Cruz TG, Liz?e G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40. PMID: 22850568; PMCID: PMC3463754.
      Citations: 142     Fields:    Translation:HumansCells
    298. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408):500-4. PMID: 22763439; PMCID: PMC3711467.
      Citations: 805     Fields:    Translation:HumansCells
    299. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63. PMID: 22817889; PMCID: PMC3600117.
      Citations: 1160     Fields:    Translation:HumansCells
    300. Cogdill AP, Frederick DT, Cooper ZA, Garber HR, Ferrone CR, Fiedler A, Rosenberg L, Thayer SP, Warshaw AL, Wargo JA. Targeting the MAGE A3 antigen in pancreatic cancer. Surgery. 2012 Sep; 152(3 Suppl 1):S13-8. PMID: 22770803; PMCID: PMC3806055.
      Citations: 6     Fields:    Translation:HumansCells
    301. Valsangkar NP, Morales-Oyarvide V, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fern?ndez-del Castillo C. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012 Sep; 152(3 Suppl 1):S4-12. PMID: 22770958; PMCID: PMC3806101.
      Citations: 122     Fields:    Translation:Humans
    302. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Lillemoe KD, Warshaw AL, Fern?ndez-del Castillo C. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012 Sep; 152(3 Suppl 1):S43-9. PMID: 22763261; PMCID: PMC3806092.
      Citations: 63     Fields:    Translation:Humans
    303. Nehra D, Oyarvide VM, Mino-Kenudson M, Thayer SP, Ferrone CR, Wargo JA, Muzikansky A, Finkelstein D, Warshaw AL, Castillo CF. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology. 2012 Jul-Aug; 12(4):358-63. PMID: 22898638; PMCID: PMC3806100.
      Citations: 9     Fields:    Translation:Humans
    304. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6. PMID: 22622578; PMCID: PMC3367798.
      Citations: 356     Fields:    Translation:HumansCells
    305. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012 Mar; 2(3):227-35. PMID: 22448344; PMCID: PMC3308191.
      Citations: 410     Fields:    Translation:HumansAnimalsCells
    306. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90. PMID: 22113612; PMCID: PMC3266695.
      Citations: 674     Fields:    Translation:HumansAnimalsCells
    307. Cecchini S, Correa-Gallego C, Desphande V, Ligorio M, Dursun A, Wargo J, Warshaw AL, Ferrone CR, Fern?ndez-del Castillo C. Superior prognostic importance of perineural invasion vs. lymph node involvement after curative resection of duodenal adenocarcinoma. J Gastrointest Surg. 2012 Jan; 16(1):113-20; discussion 120. PMID: 22005894.
      Citations: 16     Fields:    Translation:Humans
    308. Ferrone CR, Konstantinidis IT, Sahani DV, Wargo JA, Fernandez-del Castillo C, Warshaw AL. Twenty-three years of the Warshaw operation for distal pancreatectomy with preservation of the spleen. Ann Surg. 2011 Jun; 253(6):1136-9. PMID: 21394008.
      Citations: 43     Fields:    Translation:Humans
    309. Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fern?ndez-del Castillo C. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg. 2011 May; 146(5):534-8. PMID: 21576607; PMCID: PMC3688044.
      Citations: 63     Fields:    Translation:Humans
    310. Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol. 2011 Jan 15; 186(2):685-96. PMID: 21149604; PMCID: PMC6292200.
      Citations: 82     Fields:    Translation:HumansAnimalsCells
    311. Konstantinidis IT, Dursun A, Zheng H, Wargo JA, Thayer SP, Fernandez-del Castillo C, Warshaw AL, Ferrone CR. Metastatic tumors in the pancreas in the modern era. J Am Coll Surg. 2010 Dec; 211(6):749-53. PMID: 21109158; PMCID: PMC3135384.
      Citations: 45     Fields:    Translation:Humans
    312. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72. PMID: 21107320; PMCID: PMC3058384.
      Citations: 688     Fields:    Translation:HumansCells
    313. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 01; 70(13):5213-9. PMID: 20551059.
      Citations: 326     Fields:    Translation:HumansCells
    314. Correa-Gallego C, Ferrone CR, Thayer SP, Wargo JA, Warshaw AL, Fern?ndez-Del Castillo C. Incidental pancreatic cysts: do we really know what we are watching? Pancreatology. 2010; 10(2-3):144-50. PMID: 20484954; PMCID: PMC3214832.
      Citations: 73     Fields:    Translation:Humans
    315. Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol. 2010 Jun 01; 184(11):5988-98. PMID: 20427771; PMCID: PMC6290481.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    316. Konstantinidis IT, Deshpande V, Zheng H, Wargo JA, Fernandez-del Castillo C, Thayer SP, Androutsopoulos V, Lauwers GY, Warshaw AL, Ferrone CR. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma? J Gastrointest Surg. 2010 Feb; 14(2):261-7. PMID: 19937477; PMCID: PMC3135335.
      Citations: 15     Fields:    Translation:Humans
    317. Wargo JA, Tanabe K. Surgical management of melanoma. Hematol Oncol Clin North Am. 2009 Jun; 23(3):565-81, x. PMID: 19464603.
      Citations: 5     Fields:    Translation:Humans
    318. Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS, Rosenberg SA, Morgan RA. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother. 2009 Mar; 58(3):383-94. PMID: 18677478; PMCID: PMC2684457.
      Citations: 47     Fields:    Translation:HumansCells
    319. Singh AK, Sahani DV, Blake MA, Joshi MC, Wargo JA, Fernandez-del Castillo C. Assessment of pancreatic tumor resectability with multidetector computed tomography: semiautomated console-generated images versus dedicated workstation-generated images. Acad Radiol. 2008 Aug; 15(8):1058-68. PMID: 18620126.
      Citations: 1     Fields:    Translation:Humans
    320. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008 May 01; 180(9):6116-31. PMID: 18424733; PMCID: PMC2424230.
      Citations: 164     Fields:    Translation:HumansCells
    321. Shah ZK, Uppot RN, Wargo JA, Hahn PF, Sahani DV. Small bowel obstruction: the value of coronal reformatted images from 16-multidetector computed tomography--a clinicoradiological perspective. J Comput Assist Tomogr. 2008 Jan-Feb; 32(1):23-31. PMID: 18303284.
      Citations: 3     Fields:    Translation:Humans
    322. Wargo JA, Warshaw AL. Surgical approach to pancreatic exocrine neoplasms. Minerva Chir. 2005 Dec; 60(6):445-68. PMID: 16401999.
      Citations:    Fields:    Translation:Humans
    323. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27. PMID: 15775996.
      Citations: 11     Fields:    Translation:AnimalsCells
    324. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67. PMID: 15314544.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    325. Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9. PMID: 15067052.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    326. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology. 1-9.
    327. Clinicopathological features and clinical outcomes associated with TP53 and BRAFN on- V 600 mutations in cutaneous melanoma patients. Cancer.
    328. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation. 126:1834-1856.
    329. Erratum. Nature Medicine. 18:1857.
    330. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 167:397-404.e9.
    331. Cancer Discovery. 6:202-216.
    332. SFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 532:250-254.
    333. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene.
    334. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 9.
    335. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discovery. 5:274-287.
    336. Monitoring immune responses in the tumor microenvironment. Current Opinion in Immunology. 41:23-31.
    337. Implementation of a pan-genomic approach to investigate holobiont-infecting microbe interaction. PLoS One. 10.
    338. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine. 14.
    339. Landscape of targeted anti-cancer drug synergies in melanoma identifies a novel BRAF-VEGFR/PDGFR combination treatment. PLoS One. 10.
    340. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. OncoImmunology. 2.
    341. Targeted therapies combined with immune checkpoint therapy. Cancer Journal (United States). 22:138-146.
    342. Cancer Genomics in Clinical Context. Trends in Cancer. 1:36-43.
    343. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 29:270-284.
    344. Cancer Discovery. 4:1214-1229.
    345. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports. 11:1458-1473.
    346. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.
    347. YAP in MAPK pathway targeted therapy resistance. Cell Cycle. 14:1765-1766.
    348. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biology and Medicine. 11:237-246.
    349. Does it MEK a difference? Understanding immune effects of targeted therapy. Clinical Cancer Research. 21:3102-3104.
    350. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology. 5.
    351. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. Oncotarget. 7:6448-6459.
    352. Uveal melanoma. Cancer.
    353. MITF modulates therapeutic resistance through EGFR signaling. Journal of Investigative Dermatology. 135:1863-1872.
    354. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Molecular Cancer Therapeutics. 15:2442-2454.
    355. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology. 44:158-176.
    356. BRAF inhibition generates a host-tumor niche that mediates therapeutic escape. Journal of Investigative Dermatology. 135:3115-3124.
    357. Working with human tissues for translational cancer research. Journal of Visualized Experiments. 2015.
    358. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. Clinical Cancer Research. 22:5553-5563.
    359. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. OncoImmunology. 2.
    360. Association of Vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. Journal of Clinical Oncology. 34:1741-1747.
    361. Future perspectives in melanoma research. Journal of Translational Medicine. 14.
    362. Combination BRAF-Directed Therapy and Immunotherapy. Cancer Drug Discovery and Development. 82-168:163-182.
    363. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Current Oncology Reports. 18.
    WARGO's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (821)
    Explore
    _
    Co-Authors (273)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _